Reversible Neurological Adverse Reaction to Apixaban

  • Eduardo Rodrigues Cernadas Centro Hospitalar Universitário Cova da Beira, Covilhã, Portugal
  • Catarina Dionisio Centro Hospitalar Universitário Cova da Beira, Covilhã, Portugal
  • Dalia Estevão Centro Hospitalar Universitário Cova da Beira, Covilhã, Portugal
  • Leopoldina Vicente Centro Hospitalar Universitário Cova da Beira, Covilhã, Portugal

Keywords

Apixaban, neurological symptoms, adverse drug reaction

Abstract

Prescriptions for the novel oral anticoagulant factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) have equalled or exceeded those for vitamin K antagonists in many clinical settings requiring chronic anticoagulation, and those of injectable heparins for deep vein thrombosis prophylaxis. The authors report the case of an 80-year-old woman followed by her cardiologist for permanent atrial fibrillation who was prescribed apixaban. Within a few days the patient developed neurological symptoms of imbalance and non-vertiginous dizziness, headache, confusion/disorientation and asthenia. Her symptoms began to resolve after the drug was stopped, with return to baseline function within 72 h. The plasma concentration of apixaban was 4 times higher than the laboratory upper limit of normal. Symptoms did not recur when the patient was switched to rivaroxaban therapy.

VIEW THE ENTIRE ARTICLE

References

  • Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365(11):981–992.
  • Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2014;129(23):e521–e643.
  • Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369(9):799–808.
  • Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369(22):2093–2104.
  • Frost C, Shenker A, Gandhi MD, Pursley J, Barrett YC, Wang J, et al. Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. Br J Clin Pharmacol 2014;78(4):877–885.
  • Published: 2021-04-16

    Issue: 2021: Vol 8 No 4 (view)

    Section: Articles

    How to cite:
    1.
    Cernadas ER, Dionisio C, Estevão D, Vicente L. Reversible Neurological Adverse Reaction to Apixaban. EJCRIM 2021;8 doi:10.12890/2021_001739.

    Most read articles by the same author(s)